Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
Sagimet Biosciences (Nasdaq: SGMT) announced its participation in the 9th Annual MASH Drug Development Summit from September 29-October 1, 2025, in Boston. The company will deliver two oral presentations and participate in a panel discussion focused on their FASN inhibitor denifanstat.
Dr. Marie O'Farrell will present findings on denifanstat's mechanism of action in MASH, including combination treatments with semaglutide and resmetirom, highlighting results from the Phase 2b FASCINATE-2 study. Dr. Wen-Wei Tsai will discuss the application of AI-based digital pathology in evaluating denifanstat's anti-fibrotic effects in MASH patients with F3 fibrosis.
Sagimet Biosciences (Nasdaq: SGMT) ha annunciato la sua partecipazione al 9° Annual MASH Drug Development Summit, che si terrà dal 29 settembre al 1 ottobre 2025 a Boston. L'azienda terrà due presentazioni orali e prenderà parte a un panel dedicato al suo inibitore FASN, denifanstat.
La Dott.ssa Marie O'Farrell presenterà a MASH i dati sul meccanismo d'azione di denifanstat, incluse le combinazioni terapeutiche con semaglutide e resmetirom, con particolare riferimento ai risultati dello studio di Fase 2b FASCINATE-2. Il Dott. Wen-Wei Tsai parlerà dell'impiego della patologia digitale basata su AI per valutare gli effetti anti-fibrotici di denifanstat nei pazienti MASH con fibrosi di grado F3.
Sagimet Biosciences (Nasdaq: SGMT) anunció su participación en el 9.º Summit Anual sobre Desarrollo de Fármacos para MASH, que se celebrará del 29 de septiembre al 1 de octubre de 2025 en Boston. La compañía ofrecerá dos presentaciones orales y participará en un panel centrado en su inhibidor de FASN, denifanstat.
La Dra. Marie O'Farrell expondrá en MASH los hallazgos sobre el mecanismo de acción de denifanstat, incluyendo tratamientos combinados con semaglutida y resmetirom, destacando los resultados del estudio de fase 2b FASCINATE-2. El Dr. Wen-Wei Tsai abordará la aplicación de la patología digital basada en IA para evaluar los efectos anti-fibróticos de denifanstat en pacientes con MASH y fibrosis F3.
Sagimet Biosciences (나스닥: SGMT)는 2025년 9월 29일부터 10월 1일까지 보스턴에서 열리는 제9회 연례 MASH 약물개발 서밋에 참여한다고 발표했습니다. 회사는 두 건의 구두 발표를 하고 FASN 억제제인 데니판스타트(denifanstat)를 주제로 한 패널 토론에 참여할 예정입니다.
Marie O'Farrell 박사는 MASH에서 데니판스타트의 작용 기전에 대한 연구 결과를 발표하며, 세마글루타이드(semaglutide)와 레스메티롬(resmetirom)과의 병용 치료 결과와 Fase 2b FASCINATE-2 연구의 주요 성과를 강조할 예정입니다. Wen-Wei Tsai 박사는 AI 기반 디지털 병리학을 활용해 F3 섬유증을 가진 MASH 환자에서 데니판스타트의 항섬유화 효과를 평가한 내용을 발표할 것입니다.
Sagimet Biosciences (Nasdaq : SGMT) a annoncé sa participation au 9e sommet annuel sur le développement de médicaments pour le MASH, qui se tiendra du 29 septembre au 1er octobre 2025 à Boston. La société donnera deux présentations orales et participera à un panel consacré à son inhibiteur de FASN, le denifanstat.
La Dre Marie O'Farrell présentera à MASH les données sur le mécanisme d'action du denifanstat, y compris des traitements en combinaison avec le sémaglutide et le resmetirom, en mettant en avant les résultats de l'étude de phase 2b FASCINATE‑2. Le Dr Wen‑Wei Tsai expliquera l'utilisation de la pathologie numérique basée sur l'IA pour évaluer les effets anti‑fibrotiques du denifanstat chez des patients MASH présentant une fibrose de stade F3.
Sagimet Biosciences (Nasdaq: SGMT) gab bekannt, dass das Unternehmen am 9. Annual MASH Drug Development Summit teilnimmt, der vom 29. September bis 1. Oktober 2025 in Boston stattfindet. Sagimet wird zwei Vorträge halten und an einer Podiumsdiskussion zu seinem FASN-Inhibitor Denifanstat teilnehmen.
Dr. Marie O'Farrell wird auf dem MASH-Kongress Ergebnisse zum Wirkmechanismus von Denifanstat vorstellen, darunter Kombinationstherapien mit Semaglutid und Resmetirom, und dabei Ergebnisse der Phase‑2b‑Studie FASCINATE‑2 hervorheben. Dr. Wen‑Wei Tsai wird den Einsatz KI‑gestützter digitaler Pathologie zur Bewertung der antifibrotischen Effekte von Denifanstat bei MASH-Patienten mit F3‑Fibrose darlegen.
- None.
- None.
SAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company will give two oral presentations and participate in a drug development panel at the 9th Annual MASH Drug Development Summit taking place September 29-October 1, 2025 in Boston, MA. The two presentations will cover combination treatment with a FASN inhibitor, and AI-based digital pathology to evaluate denifanstat anti-fibrotic effect in MASH patients respectively.
| Presentation Title: | Highlighting Mechanism of Action of FASN Inhibitor Denifanstat in MASH |
| Presenter: | Marie O’Farrell, Ph.D., Senior Vice President of Research and Development, Sagimet Biosciences |
| Session: | Revolutionizing MASH Therapy Development by Harnessing Biomarkers & Innovative Trial Designs to Accelerate Progress Towards Effective Combination & Sequential Therapies |
| Date and time: | Monday, September 29, 2025, 2.45pm ET |
| Key Highlights: | This presentation will focus on reviewing the preclinical activity of a FASN inhibitor combined with semaglutide or resmetirom and will highlight the efficacy of denifanstat when added to background GLP1 treatment in the Phase 2b FASCINATE-2 study. Dr. O’Farrell will also cover the planned Phase 1 PK study of denifanstat and resmetirom. |
| Panel Discussion: | Designing Therapies with Novel Mechanisms & Predictive Biomarkers to Holistically Improve Treatment for Better Patient Outcomes |
| Presenter: | Marie O’Farrell, Ph.D., Senior Vice President of Research and Development, Sagimet Biosciences |
| Session: | Revolutionizing MASH Therapy Development by Harnessing Biomarkers & Innovative Trial Designs to Accelerate Progress Towards Effective Combination & Sequential Therapies |
| Date and time: | Monday, September 29, 2025, 3.15pm ET |
| Presentation Title: | Utilizing AI-Based Digital Pathology to Evaluate Denifanstat’s Anti-Fibrotic Effect in MASH Patients with Advanced Fibrosis |
| Presenter: | Wen-Wei Tsai, Ph.D., Senior Director R&D, Translational Sciences, Sagimet Biosciences |
| Session: | Revolutionizing MASH Diagnosis Using Non-Invasive Biomarkers to Enhance Precision for Earlier Detection to Improve Patient Outcomes |
| Date and time: | Tuesday, September 30, 2025, 12.45pm ET |
| Key Highlights: | This presentation will discuss the mechanism of action for denifanstat and its robust anti-fibrotic effect in MASH patients with F3 fibrosis as well as the application of digital pathology techniques to assess this anti-fibrotic effect. Dr. Tsai will also discuss the use of zonal analysis to explore denifanstat’s potential to offer long-term clinical benefit. |
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. For additional information about Sagimet, please visit www.sagimet.com.
About MASH
Metabolic-dysfunction associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there are few approved treatments. In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver. The goal of the name change was to establish an affirmative, non-stigmatizing name and diagnosis.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions.
The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates Sagimet may develop; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
When is Sagimet Biosciences (SGMT) presenting at the MASH Drug Development Summit 2025?
What will Sagimet Biosciences present about denifanstat at the MASH Summit?
Who are the presenters from Sagimet (SGMT) at the 2025 MASH Summit?
Where is the 2025 MASH Drug Development Summit being held?
